ECM
MRNA icon

ETrade Capital Management’s Moderna MRNA Stock Holding History

ETrade Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$803K Buy
+11,354
New +$792K 0.02% 441

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ETrade Capital Management's MRNA Position: Q3 2020 in Review

ETrade Capital Management opened a new position in Moderna (MRNA) in Q3 2020: 11,354 shares worth $803K. The stake represents 0.02% of the portfolio and ranks #441 among its holdings.

547 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

  • ETrade Capital Management held 11,354 shares of Moderna worth $803K as of Q3 2020.
  • Moderna was a new ETrade Capital Management position in Q3 2020.
  • Moderna made up 0.02% of ETrade Capital Management's portfolio in Q3 2020, its #441 holding.
  • 547 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.